Interferons and Dry Eye in Sjögren’s Syndrome
AbstractVarious cytokines, including interferon (IFN)-γ and IL-17, are augmented, and autoreactive T cells and B cells are activated in the immune pathogenesis of Sjögren’s syndrome (SS). In particular, IFNs are involved in both the early stages of innate immunity by high level of type I IFN in glandular tissue and sera and the later stages of disease progression by type I and type II IFN producing T cells and B cells through B cell activating factor in SS. Genetically modified mouse models for some of these molecules have been reported and will be discussed in this review. New findings from human SS and animal models of SS have elucidated some of the mechanisms underlying SS-related dry eye. We will discuss IFN-γ and several other molecules that represent candidate targets for treating inflammation in SS-related dry eye. View Full-Text
Share & Cite This Article
Ogawa, Y.; Shimizu, E.; Tsubota, K. Interferons and Dry Eye in Sjögren’s Syndrome. Int. J. Mol. Sci. 2018, 19, 3548.
Ogawa Y, Shimizu E, Tsubota K. Interferons and Dry Eye in Sjögren’s Syndrome. International Journal of Molecular Sciences. 2018; 19(11):3548.Chicago/Turabian Style
Ogawa, Yoko; Shimizu, Eisuke; Tsubota, Kazuo. 2018. "Interferons and Dry Eye in Sjögren’s Syndrome." Int. J. Mol. Sci. 19, no. 11: 3548.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.